Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety Funding To Increase By $10 Mil. Under FDA Appropriations

Executive Summary

The Agriculture Appropriations conference report approved by the House and Senate doubles the Administration's requested increase in drug safety funding for FDA to $10 mil
Advertisement

Related Content

Authorized Generics’ Impact On Medicaid Pricing To Be Focus Of HHS Study
Authorized Generics’ Impact On Medicaid Pricing To Be Focus Of HHS Study
PDUFA IV: FDA Stresses Burden Of Industry Meetings In User Fee Discussions
PDUFA IV: FDA Stresses Burden Of Industry Meetings In User Fee Discussions
Authorized Generics Noose Tightens With “Best Price” Proposal, FTC Study
Authorized Generics Noose Tightens With “Best Price” Proposal, FTC Study
FDA Report On Citizen Petition Impact On ANDAs Sought By Senate Panel
FDA Report On Citizen Petition Impact On ANDAs Sought By Senate Panel
FTC Should Study Competitive Impact Of “Authorized” Generics, Senators Say

Topics

Advertisement
UsernamePublicRestriction

Register

PS046514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel